Where Healthcare Investors Are Placing Their Next Big Bets

After years of rapid digital transformation and abundant capital, the market has become increasingly selective, rewarding businesses that can demonstrate scalable growth, measurable clinical impact, and sustainable competitive advantages. Across healthcare services and digital health alike, investors are shifting their focus from disruptive ideas to proven execution, creating new opportunities for companies capable of integrating technology, improving care delivery, and building durable platforms.

This report explores four trends defining that transition. We examine why behavioral health is emerging as the sector's leading consolidation opportunity, the barriers preventing digital health companies from reaching enterprise scale, the growing importance of Clinical Decision Support as the next frontier for AI-enabled healthcare, and how venture capital is increasingly concentrating around companies with proven commercial traction. 

Together, these themes provide a snapshot of where healthcare investment is heading, and the characteristics that will define the industry's next generation of market leaders.

Behavioral Health Leads the Next Wave of Healthcare Services Consolidation

The healthcare services M&A market has become increasingly selective, but not less active. Rather than pursuing broad-based platform investments, private equity firms and strategic acquirers are concentrating capital in subsectors that combine strong secular demand, fragmented provider landscapes, and meaningful opportunities for operational improvement. 

As financing costs remain elevated and reimbursement pressures persist across several areas of healthcare, investors are placing a greater premium on businesses capable of delivering resilient growth, recurring patient demand, and scalable operating models. Against this backdrop, consolidation is no longer occurring evenly across healthcare services—it is becoming concentrated in the areas where demographic, regulatory, and clinical trends align most favorably.

Behavioral health has emerged as perhaps the clearest beneficiary of this shift. Years of underinvestment, worsening provider shortages, expanding payer support for mental health services, and growing societal awareness have created an environment where demand consistently exceeds available capacity. The sector remains highly fragmented, with thousands of independent providers lacking the scale necessary to invest in technology, value-based care capabilities, clinical recruitment, and administrative infrastructure. These characteristics have made behavioral health particularly attractive for platform-building strategies, allowing sponsors to generate value through geographic expansion, operational standardization, and add-on acquisitions. 

While physician practice management continues to represent an attractive consolidation opportunity across several specialties, increased regulatory scrutiny surrounding management service organizations (MSOs) and physician ownership structures has introduced additional complexity into deal execution. Meanwhile, home-based care continues to benefit from powerful demographic tailwinds, but reimbursement variability and labor shortages have tempered expectations for the pace of consolidation relative to other healthcare services segments.

Healthcare150's latest proprietary survey reflects how investors are prioritizing these dynamics. Half of respondents identified behavioral health as the healthcare services segment most likely to experience increased consolidation over the next 24 months, significantly ahead of physician practice management (33%) and home-based care (17%). The findings suggest that market participants increasingly view behavioral health as the sector offering the strongest combination of demand growth, market fragmentation, and scalable investment opportunities. Rather than simply identifying where deal volume may increase, the survey highlights where investors believe the next generation of healthcare platforms will likely be built—and where competition for high-quality assets is expected to intensify.

Chart Analysis

• Behavioral health clearly stands apart as investors' highest-conviction consolidation opportunity, capturing 50% of survey responses and outperforming every other healthcare services category.

• The results reinforce a structural investment thesis rather than a cyclical one. Behavioral health benefits from long-term demographic and public health trends that are expected to persist regardless of broader economic conditions.

• Extreme market fragmentation continues to create favorable acquisition economics. Thousands of independent behavioral health providers remain potential acquisition targets for both private equity-backed platforms and strategic consolidators.

• Provider shortages increase the strategic value of scaled organizations. Larger platforms are better positioned to recruit clinicians, negotiate payer contracts, invest in technology, and expand access across multiple care settings.

• Physician practice management remains a major consolidation theme despite increased regulatory complexity. Specialty physician groups continue attracting investor interest, although heightened scrutiny of PE-backed physician transactions has made execution more selective.

• Home-based care remains an attractive long-term market but ranks behind behavioral health in expected consolidation. Investors continue to recognize strong demographic tailwinds, although reimbursement uncertainty and workforce availability present ongoing operational challenges.

• Capital allocation is increasingly favoring sectors with multiple value-creation levers. Investors are seeking businesses where operational improvement, geographic expansion, technology adoption, and add-on acquisitions can collectively drive EBITDA growth.

• The survey reflects broader changes in private equity strategy. Rather than pursuing healthcare services indiscriminately, firms are concentrating investments in subsectors where scale creates meaningful competitive advantages.

• Strategic buyers are likely to compete alongside financial sponsors. Health systems, national provider organizations, and large care delivery platforms continue pursuing acquisitions that expand clinical capabilities while improving care coordination.

• Behavioral health may also become an important testing ground for AI-enabled care delivery and workforce optimization. Technology-supported clinical workflows, digital intake, scheduling automation, and documentation tools could further improve the scalability of larger behavioral health organizations.

• For investors, the message is clear: healthcare consolidation is entering a more focused phase, and behavioral health appears positioned to capture a disproportionate share of acquisition activity, capital deployment, and platform creation over the coming investment cycle.

The Enterprise Adoption Gap: Why Digital Health Still Struggles to Scale

The digital health industry has entered a new phase of maturity. The exuberance that characterized the post-pandemic funding boom has given way to a more disciplined market where health systems, payers, and investors expect measurable operational and clinical outcomes before committing to enterprise-wide deployments. While innovation continues at a rapid pace—particularly in artificial intelligence, remote monitoring, clinical decision support, and patient engagement—the challenge is no longer proving that digital solutions can work. Instead, success increasingly depends on demonstrating that they can integrate seamlessly into complex healthcare organizations, improve workflows, and generate sustainable financial returns. For digital health companies, the path from successful pilot program to enterprise-scale adoption remains one of the industry's most significant hurdles.

The barriers to scaling are largely structural rather than technological. Health systems operate within highly fragmented IT environments built around electronic health records, legacy infrastructure, complex procurement processes, and multiple clinical stakeholders, making implementation significantly more difficult than in most other industries. At the same time, healthcare executives have become increasingly selective as operating margins remain under pressure, requiring digital solutions to demonstrate clear clinical impact, operational efficiencies, or measurable financial returns before expanding beyond limited deployments. Reimbursement uncertainty further complicates commercialization, particularly for solutions whose value depends on payment models that continue to evolve alongside value-based care initiatives. As a result, many promising digital health companies successfully complete pilot programs but struggle to achieve broad enterprise adoption due to integration challenges, unclear return on investment, or misaligned reimbursement incentives rather than deficiencies in the underlying technology itself.

Healthcare150's latest proprietary survey highlights how industry leaders perceive these obstacles. Nearly four in ten respondents identified difficult health systems as the primary barrier preventing digital health companies from reaching enterprise scale, followed closely by unclear clinical ROI (31%) and weak reimbursement models (30%). The close distribution across all three responses underscores an important reality: enterprise adoption is rarely constrained by a single issue. Instead, scaling digital health requires simultaneously addressing clinical validation, financial incentives, implementation complexity, and organizational change. The survey suggests that the next generation of market leaders will not necessarily be those with the most innovative technologies, but rather those capable of embedding their solutions into the operational fabric of modern healthcare organizations.

Chart Analysis

• Health system complexity emerged as the industry's largest scaling obstacle, with 39% of respondents identifying enterprise adoption itself—not product innovation—as the primary bottleneck.

• Healthcare remains one of the most difficult enterprise sales environments across any industry. Purchasing decisions often involve clinical leadership, IT departments, finance teams, procurement, compliance, cybersecurity, and executive management, substantially extending implementation timelines.

• Integration has become a competitive differentiator. Digital health companies that integrate seamlessly with existing EHRs, clinical workflows, and administrative systems are significantly better positioned to move beyond isolated pilot programs into enterprise-wide deployments.

• Clinical evidence alone is no longer sufficient. With 31% of respondents citing unclear clinical ROI, buyers increasingly require measurable improvements in patient outcomes, clinician productivity, operational efficiency, or total cost of care before approving large-scale implementations.

• Executive buyers are shifting from innovation metrics to business metrics. Rather than evaluating adoption rates or feature utilization alone, health systems increasingly assess technologies based on financial performance, workforce impact, and workflow transformation.

• Weak reimbursement models remain a nearly equal concern, reflecting the reality that many digital health solutions still operate within payment structures that do not consistently reward technology-enabled care delivery.

• The narrow spread between all three responses is notable. No single barrier dominates the market, suggesting that enterprise-scale success requires companies to execute across technology, clinical validation, commercial strategy, and reimbursement simultaneously.

• Artificial intelligence does not eliminate these challenges—it often amplifies them. As AI-enabled healthcare solutions proliferate, providers demand even stronger governance, workflow integration, validation, and measurable economic outcomes before deploying them at scale.

• For investors, commercialization risk increasingly outweighs technology risk. Companies with proven enterprise implementation capabilities, established health system partnerships, and repeatable deployment models may command premium valuations despite operating in competitive markets.

• The survey reinforces a broader shift in digital health investing. Capital is flowing away from companies built around compelling demonstrations and toward businesses capable of consistently delivering enterprise adoption, measurable ROI, and scalable commercial execution.

• The bottom line: the future winners in digital health will be determined less by who builds the most sophisticated technology and more by who best navigates the operational realities of modern healthcare delivery.

Clinical Intelligence Is Becoming Digital Health's Next Defining Platform

Every wave of digital health innovation has been defined by a new infrastructure layer. The first generation focused on digitizing access through telehealth, online scheduling, patient engagement, and remote care delivery. More recently, the industry shifted toward connected devices, virtual-first care models, and remote patient monitoring that extended healthcare beyond the walls of traditional clinical settings. Today, however, the market is entering another transition. Rather than simply connecting patients with providers, the next generation of digital health companies is increasingly focused on improving the quality, speed, and consistency of clinical decision-making itself. Artificial intelligence has accelerated this shift, enabling software to move beyond administrative automation and begin supporting diagnosis, treatment recommendations, documentation, care coordination, and workflow optimization directly within the clinical environment.

This evolution is fundamentally changing how investors evaluate digital health opportunities. The largest value creation opportunities increasingly reside in platforms that become embedded within everyday clinical workflows rather than those operating alongside them. Clinical Decision Support (CDS) platforms have emerged as a particularly attractive category because they sit at the intersection of artificial intelligence, electronic health records, real-world clinical data, and provider productivity. Unlike many digital health applications that depend primarily on patient engagement, CDS solutions generate value across multiple stakeholders simultaneously by helping clinicians make faster, more informed decisions while improving quality metrics, reducing medical errors, and enhancing operational efficiency. Virtual care platforms continue to represent an important component of modern healthcare delivery, while remote patient monitoring remains a promising long-term growth market, particularly for chronic disease management. However, both categories increasingly depend on intelligent software capable of interpreting clinical information rather than simply collecting or transmitting it. Industry forecasts reflect this momentum, with the global Clinical Decision Support Systems market expected to surpass $10 billion by 2031 as adoption accelerates across hospitals and health systems.

Healthcare150's latest proprietary survey captures this changing investment narrative. More than half of respondents (54%) believe Clinical Decision Support will produce the next $10 billion digital health company, comfortably ahead of Virtual Care Platforms (30%) and Remote Patient Monitoring (16%). The results suggest investors increasingly believe the next generation of healthcare technology leaders will be built not around expanding access to care, but around improving the intelligence behind clinical decision-making. As artificial intelligence becomes deeply integrated into provider workflows, competitive advantage is shifting toward companies capable of becoming indispensable components of everyday clinical practice rather than standalone digital health applications.

Chart Analysis

• Clinical Decision Support emerged as the clear market favorite, with 54% of respondents identifying it as the digital health category most likely to create the next $10 billion company.

• The results reflect a broader evolution in digital health investing. Earlier investment cycles prioritized expanding healthcare access through telemedicine and remote engagement, whereas today's investors increasingly favor technologies that directly improve clinical productivity and decision quality.

• Artificial intelligence is accelerating this transition. Large language models, predictive analytics, ambient documentation, and real-time decision support are transforming CDS platforms from reference tools into embedded clinical copilots capable of supporting providers throughout the patient journey.

• Clinical workflow integration represents a powerful competitive advantage. Solutions that operate directly within electronic health records and existing provider workflows create higher switching costs, stronger customer retention, and more durable enterprise relationships than standalone applications.

• Virtual Care Platforms remain an attractive investment category, capturing 30% of responses and reflecting the continued importance of hybrid care delivery models. However, the market increasingly views virtual care as an established delivery channel rather than the primary driver of future platform value.

• Remote Patient Monitoring ranked third despite favorable long-term demographics. While RPM continues to benefit from aging populations and chronic disease prevalence, investors increasingly recognize that the greatest value may reside in interpreting patient data rather than simply collecting it.

• The survey suggests the market is shifting from connectivity to intelligence. Healthcare organizations no longer seek technologies that merely digitize existing processes—they increasingly prioritize platforms that improve clinical decisions, automate cognitive work, and enhance provider productivity.

• Enterprise adoption further strengthens the CDS investment thesis. Once integrated into physician workflows, clinical decision support platforms often become mission-critical infrastructure, creating recurring revenue opportunities and long-term customer relationships.

• The category also benefits from multiple value creation pathways. Beyond direct software revenue, CDS platforms can expand into documentation, quality measurement, care management, coding, utilization management, revenue cycle optimization, and population health analytics.

• For private equity and venture investors, scalability has become increasingly important. Clinical Decision Support combines large addressable markets, recurring enterprise revenue, high customer retention, and growing AI differentiation—characteristics commonly associated with category-defining software businesses.

• The bottom line: the next generation of digital health leaders is likely to be built around clinical intelligence rather than digital access, positioning Clinical Decision Support as one of the most compelling investment opportunities in healthcare technology over the coming decade.

The New Funding Playbook: Digital Health Capital Is Concentrating Around Proven Winners

The digital health funding environment has entered a markedly different phase from the exuberant investment cycle that followed the pandemic. While venture capital activity has recovered from the market correction of 2022 and 2023, investors have become substantially more disciplined in how they deploy capital. Rather than broadly funding early-stage innovation across dozens of healthcare technology categories, today's market increasingly rewards companies that have demonstrated commercial traction, enterprise adoption, and scalable business models. The result is a funding landscape defined less by the total amount of capital available and more by where that capital is flowing. Investors are writing larger checks, but to a much smaller group of companies capable of solving complex healthcare challenges at enterprise scale.

Artificial intelligence has become the primary catalyst behind this shift, but not in the way many expected. AI is no longer viewed as a competitive advantage on its own—it has become a baseline expectation across digital health. Instead, investors are differentiating companies based on how effectively they embed AI into clinical workflows, provider operations, reimbursement processes, and care delivery rather than simply marketing AI-enabled products. This evolution has created a pronounced "winner-takes-more" dynamic, where companies with validated commercial models are attracting increasingly larger funding rounds while capital becomes more selective elsewhere in the market. At the same time, improving policy support for interoperability, continued telehealth flexibility, and growing enterprise demand for workflow automation are reinforcing investor confidence in businesses capable of delivering measurable operational value. As digital health matures, scale, execution, and integration have become more important than novelty.

Rock Health's Q1 2026 funding data illustrates this transformation clearly. Digital health startups raised $4 billion during the quarter across 110 transactions, representing the strongest first quarter since the pandemic-era funding peak. However, nearly 60% of all invested capital was concentrated in just 12 megadeals exceeding $100 million, while average deal size climbed to $36.7 million—the highest quarterly average since late 2021. The data demonstrates that the market is not experiencing a broad-based funding recovery; instead, investors are concentrating capital behind companies with proven commercial traction and category leadership. Rather than asking whether digital health funding has returned, the more important question has become which companies are demonstrating the characteristics necessary to attract increasingly selective growth capital.

Chart Analysis

• Digital health funding reached $4 billion during Q1 2026, making it the strongest first quarter for venture investment since the post-pandemic funding surge and signaling renewed confidence in the sector.

• Capital is becoming increasingly concentrated. Twelve megadeals accounted for 59% of all funding, highlighting a market where investors are deploying larger amounts of capital into a relatively small number of proven companies rather than broadly funding early-stage startups.

• Average deal size increased to $36.7 million, the highest quarterly average since Q4 2021, reflecting investors' preference for larger growth-stage financings over smaller venture rounds.

• The funding leaders share a common characteristic: they are solving complex, workflow-embedded healthcare problems rather than offering standalone digital applications. Companies such as Whoop, OpenEvidence, Verily, Talkiatry, and eMed all operate within critical components of the healthcare ecosystem.

• Artificial intelligence has become table stakes rather than a differentiator. Investors increasingly evaluate how AI improves clinical workflows, enterprise integration, and measurable outcomes instead of simply whether a company incorporates AI into its products.

• The market increasingly resembles enterprise software investing. Companies capable of demonstrating recurring revenue, strong customer retention, scalable deployment models, and embedded workflow integration are attracting a disproportionate share of available capital.

• Healthcare delivery remains one of the largest investment themes. Several of the quarter's largest financings targeted provider enablement, virtual care, patient advocacy, and clinical intelligence, reinforcing the industry's continued digital transformation.

• The funding concentration creates a widening gap between market leaders and emerging startups. While mature companies continue raising increasingly larger rounds, early-stage businesses face a more demanding fundraising environment that requires stronger evidence of product-market fit and commercial execution.

• For private equity investors, these trends reinforce an important lesson: scale is increasingly becoming a competitive moat. Companies capable of securing significant growth capital gain advantages in product development, enterprise sales, acquisitions, and data accumulation that become increasingly difficult for smaller competitors to replicate.

• The improving funding environment does not imply indiscriminate optimism. Investors remain highly selective, favoring businesses with proven economics, experienced management teams, regulatory readiness, and scalable enterprise business models over speculative growth narratives.

• The bottom line: digital health funding has recovered, but the rules have fundamentally changed. Capital is flowing toward fewer companies with stronger execution capabilities, suggesting that the next generation of healthcare technology leaders will be defined as much by operational excellence as by technological innovation.

Across each of the trends explored in this report, a common theme emerges: healthcare is becoming a market where execution matters as much as innovation. Investors are increasingly rewarding businesses that can integrate into clinical workflows, achieve enterprise-scale adoption, build scalable platforms, and translate technological advances into measurable outcomes.

Whether through behavioral health consolidation, AI-powered clinical intelligence, or concentrated venture investment, the industry's next leaders will be those capable of combining innovation with operational excellence. As healthcare continues to evolve, sustainable value creation will increasingly belong to organizations that become essential infrastructure for providers, patients, and the broader healthcare ecosystem.

Sources & References

Fierce Healthcare. Digital Health Startups. https://www.fiercehealthcare.com/digital-health/digital-health-startups-raked-4b-q1-12-megadeals-driving-investment-rock-health

Healthcare150. Digital Health Still Struggles.https://www.healthcare150.com/p/why-digital-health-still-struggles-to-reach-enterprise-scale

Healthcare150. $10B Digital Health Company Will be Built on Clinical Intelligence.https://www.healthcare150.com/p/the-next-10b-digital-health-company-will-be-built-on-clinical-intelligence

Healthcare150. Behavioral Health Emerges as HC’s Next Consolidation Hotspot. https://www.healthcare150.com/p/behavioral-health-emerges-as-healthcare-s-next-consolidation-hotspot